MARC record from Internet Archive

LEADER: 05361cam 2200865 i 4500
001 ocm02277688
003 OCoLC
005 20181203022624.0
008 760727s1976 cau b 001 0 eng
010 $a 75027935
040 $aDLC$beng$erda$cDLC$dMQM$dUBA$dNLM$dEL$$dMUQ$dBAKER$dNLGGC$dBTCTA$dNLE$dCRU$dHLS$dUKV3G$dMOF$dYDXCP$dMMU$dGTA$dBDX$dGBVCP$dOCLCQ$dTPH$dOCLCF$dOCLCQ$dUEJ$dOCLCQ$dCSJ$dLSD$dOCLCO$dDHA$dOCLCA$dOCLCQ$dOCLCA$dCPO$dOCLCQ$dUKMGB
015 $aGB7701633$2bnb
016 7 $a7610344$2DNLM
016 7 $a052-00312$2Uk
016 7 $a008748266$2Uk
019 $a41299192$a59158698
020 $a0520031229
020 $a9780520031227
035 $a(OCoLC)2277688$z(OCoLC)41299192$z(OCoLC)59158698
043 $acl-----
050 00 $aRM301$b.S53
060 00 $aQV 736$bS587d 1976
082 00 $a614.3/5/098
083 0 $aPrescription drugs. Promotion by pharmaceutical industries. United States. Compared with promotion of prescription drugs by pharmaceutical industries in Latin America
084 $a615.7042$222
084 $a44.40$2bcl
084 $a83.67$2bcl
088 $a75027935
100 1 $aSilverman, Milton,$d1910-
245 14 $aThe drugging of the Americas :$bhow multinational drug companies say one thing about their products to physicians in the United States, and another thing to physicians in Latin America /$cby Milton Silverman.
264 1 $aBerkeley :$bUniversity of California Press,$c℗♭1976.
300 $axiv, 147 pages ;$c25 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aIntroduction -- Antibiotics -- Oral contraceptives -- Nonsteroid antiarthritics -- Steroid hormones -- Antipsychotic tranquilizers -- Antidepressants -- Anticonvulsants -- Discussion: the epidemiology of drug promotion.
520 $aIn the United States, drug companies promoting their products to physicians are required by law to limit their claims to what they can prove, and to make full disclosure of all known hazards. Dr. Silverman, a noted science writer and pharmacologist, finds that many multinational drug companies are circumventing similar laws in Latin America in order to sell more of their products. The author provides detailed comparisons of the promotion of 28 separate prescription drugs in the U.S. and in Mexico, Central America, and other Latin American countries. Typically, claims for effectiveness are exaggerated in Latin America and the hazards are glossed over. This practice, denounced by Latin American medical experts and appalling even to scientists within the drug industry, is blamed for needless patient injury and death. When called upon to explain the inconsistencies in their promotional campaigns, their standard defense is "we're not breaking any laws." But some of these global companies have been breaking laws. They have been lying. In the United States, the major pharmaceutical companies have long and vociferously assailed the laws which now require them to restrict claims of efficacy of their products to those they can support with substantial scientific evidence and to inform physicians fully of all hazards. The companies argue that these rules are excessively harsh and that these laws and regulations are not necessary because the industry recognizes its social responsibilities and would live up to them, laws or no laws. The information presented here is a partial response to such an argument. It demonstrates that a problem exists and shows how some companies comport themselves when there are no restrictive laws, or when the laws are not enforced. -- from Preface.
650 0 $aDrugs$xSide effects.
650 0 $aPharmaceutical industry$zLatin America.
650 0 $aDeceptive advertising$zLatin America.
650 2 $aAdvertising as Topic.
650 2 $aDrug Industry.
650 2 $aDrug-Related Side Effects and Adverse Reactions.
651 2 $aLatin America.
651 2 $aUnited States.
650 6 $aIndustrie pharmaceutique$zE tats-Unis.
650 6 $aIndustrie pharmaceutique$zAme rique latine.
650 7 $aDeceptive advertising.$2fast$0(OCoLC)fst00888983
650 7 $aDrugs$xSide effects.$2fast$0(OCoLC)fst00898912
650 7 $aPharmaceutical industry.$2fast$0(OCoLC)fst01060129
651 7 $aLatin America.$2fast$0(OCoLC)fst01245945
650 17 $aFarmaceutische industrie.$2gtt
650 17 $aInternationale ondernemingen.$2gtt
650 17 $aMarketing.$2gtt
650 7 $aFarmacologia Aplicada E Terapeutica.$2larpcal
653 0 $aDrug trade$aLatin America
653 0 $aDrug trade$aUnited States
938 $aBaker & Taylor$bBKTY$c39.95$d39.95$i0520031229$n0000450468$sactive
938 $aBrodart$bBROD$n27315118$c$39.95
938 $aBaker and Taylor$bBTCP$n75027935 //r952
938 $aYBP Library Services$bYANK$n3914489
029 1 $aAU@$b000000742441
029 1 $aAU@$b000003410523
029 1 $aAU@$b000023898729
029 1 $aGBVCP$b021969043
029 1 $aHR0$b0520031229
029 1 $aNLGGC$b770015042
029 1 $aNLM$b7610344
029 1 $aNZ1$b2841039
029 1 $aNZ1$b31280
029 1 $aUNITY$b005233380
029 1 $aUKMGB$b008748266
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 454 OTHER HOLDINGS